Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Recommended Dilution |
1 - 2 μg/mL |
2.5 μg/mL |
Assay dependent |
Not tested in other applications.
Calculated MW
Positive Control
Human Testis Tissue Lysate(GTX15374) , Human Testis Tissue Slide(GTX21748)
Form
Liquid
Buffer
PBS
Preservative
0.02% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
1 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
ESX1 antibody was raised against a 19 amino acid synthetic peptide near the center of human ESX1.The immunogen is located within amino acids 140 - 190 of ESX1.
Purification
Purified by antigen-affinity chromatography
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
Synonyms
ESX homeobox 1 , ESX1L , ESXR1
Cellular Localization
Cytoplasm,Nucleus
Background
Homeobox proteins are transcription factors that contain a helix-turn-helix DNA binding domain termed the homeodomain. ESX1 is an X-linked homeobox gene primarily expressed in the placenta and testis and contains two functional domains: the homeodomain and the proline-rich domain. During embryogenesis, ESX1 is expressed in the extraembryonic tissues, including the endoderm of the visceral yolk sac, the ectoderm of the chorion and the labyrinthine trophoblast of the chorioallantoic placenta. ESX1 can act like a transcriptional repressor to the human oncogene K-ras and treatment of human cancer cells with an ESX1 protein fragment containing the homeodomain reduces the tumorgenicity of cells containing oncogenic K-ras mutations, suggesting ESX1 may be useful as a therapeutic treatment for these cancers.
Database